Type I IL-1 Receptor (IL-1RI) as Potential New Therapeutic Target for Bronchial Asthma

Table 2

Effect of therapeutic experiments Targeting ST-2/IL-33 pathway.

Reagent	Mechanism	Animal model	airway hyperreactivity (AHR)	Inflammatory infiltration (eosinophils and lymphocytes)	IgE	Th1 cytokine	Th2 cytokine	Ref
antibodies against IL-33	neutralizing monoclonal Ab	Mice sensitized with ovalbumin	N.A.	$\downarrow$	$\downarrow$	$⟷$	$\downarrow$ (IL-4, IL-5, and IL-13)	[53]
antibodies against T1/ST2	blocking monoclonal	Mice sensitized with ovalbumin	$\downarrow$	N.A.	N.A.	N.A.	$\downarrow$ (IL-4); $⟷$ (IL-13)	[54]
recombinant soluble ST2 protein	soluble recepto	Mice sensitized with ovalbumin; OVA-stimulated splenocytes	N.A.	N.A.	N.A.	$\uparrow$ (IFN-$\gamma$) from stimulated splenocytes	$\downarrow$ (IL-4, IL-5, and IL-13) from IL-33-stimulated splenocytes	[42]
plasmid expressing soluble ST2	soluble receptor; gene therapy	Mice sensitized with ovalbumin	N.A.	$\downarrow$ (eosinophils)	N.A.	$\uparrow$ (IFN-γ)	$\downarrow$ (IL-4 and IL-5)	[44]